TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02357732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Study: NCT03423056

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative exercise program
Description: Individualized aerobic training program developed by physical therapist using Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks. Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed between 50 to 70% of the maximum heart rate and will be carried on a treadmill or in a stationary bicycle.
Study: NCT03343795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral progesterone
Description: daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intramuscular progesterone
Description: every week
Study: NCT02152332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911-Therapeutic Dose
Description: JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911-Therapeutic Dose
Description: JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911-Therapeutic Dose
Description: JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.
Study: NCT02812199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold saline wash
Description: nasal wash with cold saline prior to stent removal, to induce stent self-crimping.
Study: NCT01795612

Intervention type: OTHER
Group type: OTHER
Intervention: physical activity
Study: NCT00751413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK0633
Description: A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight.
Study: NCT03095287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alphanate
Description: Bolus IV injection.
Study: NCT00582517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compass Universal Hinge External Fixator
Description: Application of the Compass Knee Hinge adds approximately 30 minutes to the surgical time. After the apparatus has been in place for the appropriate amount of time (6-8 weeks), it is removed either in the clinical setting, or in the one-day surgery area of UAB Highlands.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive External Knee Brace
Description: For Group A patients, an external knee brace (several brands available and no one brace specified for this study) will be placed on the leg following surgical repair of the knee dislocation.
Study: NCT02152332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911-Therapeutic Dose
Description: JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 - Supratherapeutic Dose
Description: JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 - Supratherapeutic Dose
Description: JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 - Supratherapeutic Dose
Description: JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 - Supratherapeutic Dose
Description: JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911-Matched Placebo
Description: JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911-Matched Placebo
Description: JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911-Matched Placebo
Description: JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911-Matched Placebo
Description: JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg on Day 7 in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg on Day 7 in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg on Day 7 in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg on Day 7 in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Matched Placebo
Description: Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Matched Placebo
Description: Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Matched Placebo
Description: Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Matched Placebo
Description: Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.
Study: NCT03060421

Intervention type: DEVICE
Intervention: Aquamid reconstruction
Description: Aquamid Reconstruction is a Polyacrylamide hydrogel that contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape. Aquamid Reconstruction is biocompatible, non-absorbable non-biodegradable, stable, and sterile. T Aquamid Reconstruction is injected into the knee joint cavity.
Study: NCT04008017

Intervention type: DIAGNOSTIC_TEST
Intervention: Eosinophilic Cationic Protein biomarker
Description: 3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Eosinophilic Cationic Protein biomarker
Description: 3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
Study: NCT03766425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: subconjunctival injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin
Description: subconjunctival injection
Study: NCT02373319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CV-screening-1 plus personalized
Description: Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CV-screening-2 plus personalized
Description: Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CV-screening-1 plus standard
Description: Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CV-screening-2 plus standard
Description: Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
Study: NCT02042664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYETTA treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformine
Study: NCT04057222

Intervention type: OTHER
Intervention: No intervention
Description: Only propose water and wait for need to void
Study: NCT00280553

Intervention type: DRUG
Group type: OTHER
Intervention: bupivicaine
Description: PCA and bupivicaine infusion for up to five days

Intervention type: OTHER
Group type: OTHER
Intervention: Saline infusion
Description: PCA and pump with saline infusion for up to five days
Study: NCT00385346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Patients in the intervention group write on three day for 20 minutes about highly emotional topics In the control group patients write on three days for 20 minutes about topics with relatively low emotional involvement such as diet, time management and sport.
Study: NCT02993380

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Stir-fried olive oil group
Description: Stir-fried olive oil group taking food with extra-virgin olive oil in stir fried food or any food with olive oil in heated under 150 degrees of celsius minimal dose per week is 30gram, providing amount of olive oil with meals is 10gram, three times in a weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural olive oil group
Description: Natural olive oil group taking food with extra-virgin any food with olive oil in , minimal dose per week is 30grams, providing amount of olive oil with meals is 10gram, three times in a weeks
Study: NCT02265783

Intervention type: DEVICE
Group type: OTHER
Intervention: Nellcor USB Pulse Oximeter Monitor Interface Cable
Description: Volunteers are subjected to certain simulated, sensor removal conditions known to represent challenges to the sensor-off feature. Such conditions include exposing the sensor to an ambient light source, sensor slipping off the finger with the light emitter and detector facing each other or a sensor slipping off under a blanket.
Study: NCT03892694

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RejuvenAir System
Description: Bronchial metered cryospray using RejuvenAir® System.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham control procedure
Study: NCT02291263

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV/IPV (6 weeks)
Description: bOPV at 6, 10 and 14 weeks of age IPV at 6 weeks of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV/IPV (14 weeks)
Description: bOPV at 6, 10 and 14 weeks of age IPV at 14 weeks of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bOPV/IPV (6 & 14 weeks)
Description: bOPV at 6, 10 and 14 weeks of age IPV at 6 and14 weeks of age
Study: NCT04381962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Capsule
Description: Azithromycin 500 mg OD PO 14 days
Study: NCT01841866

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LMA removal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LMA removal
Study: NCT03204630

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lfer
Description: Probiotic bacteria originally isolated from breast milk: the strain Lactobacillus fermentum CECT5716

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifido
Description: Probiotic bacteria originally isolated from breast milk: the strain Bifidobacterium breve CECT7263

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard infant formula
Study: NCT01061008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post operative progressive handgrip exercise
Description: As soon as possible post operation the patient will commence an eight week progressive handgrip training intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Continue routine care, with removal of exercise information given to patients(if anye.g. do not give out squeeze balls)
Study: NCT01841619

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIg
Description: All enrolled subjects will receive IVIg treatment following the protocol that proved to be efficacious in the treatment of patients with autoimmune blistering diseases as well as some patients with CLE. The drug will be administered at 500 mg/kg/day on consecutive days up to a total of 2 g/kg/month for 3 months in the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine. After 3 months of treatment, IVIg will be discontinued and the subjects will be monitored for additional 6 months for a possible relapse. In the case of relapse, which is expected to occur in \<25% subjects, the subjects will be re-treated by the standard protocol.
Study: NCT00395967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF plus plerixafor
Description: Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
Study: NCT03835741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeO2
Description: an automated adjustment of oxygen during patient hospitalisation by FreeO2 device

Intervention type: OTHER
Group type: OTHER
Intervention: manual titration
Description: a manual adjustment of oxygen during patient hospitalisation by hospital staff
Study: NCT00379951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem sodium
Description: ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.
Study: NCT01781455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Study: NCT02204631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head and Neck Educational Handbook
Study: NCT02542176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze-dried Whole Grape Powder
Description: 60 g of whole grape powder for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Grape Powder Placebo
Description: 60 g of grape powder placebo for 4 weeks
Study: NCT03509324

Intervention type: DRUG
Group type: OTHER
Intervention: Insulin LISPRO
Description: receive short-term insulin pump therapy by using insulin LISPRO, continue treatment for 7 more days when euglycemia achieved
Study: NCT03041311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide IV
Study: NCT00608920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography (SPECT)
Study: NCT02503046

Intervention type: OTHER
Intervention: Estimation of Pentraxin3
Description: 5ml of blood to be collected from each subject, centrifuged, to separate the plasma for estimation of Pentraxin3 (Quantikine ELISA)

Intervention type: OTHER
Intervention: Estimation of Pentraxin3
Description: 5ml of blood to be collected from each subject, centrifuged, to separate the plasma for estimation of Pentraxin3 (Quantikine ELISA)
Study: NCT03041311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab IV
Study: NCT01299727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhHNS-10 mg
Description: Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhHNS-45 mg
Description: Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rhHNS-90 mg
Description: Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
Study: NCT00955058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCP
Description: Daily For 3 months
Study: NCT02503046

Intervention type: OTHER
Intervention: Estimation of Pentraxin3
Description: 5ml of blood to be collected from each subject, centrifuged, to separate the plasma for estimation of Pentraxin3 (Quantikine ELISA)

Intervention type: GENETIC
Intervention: Estimation of P.Gingivalis levels
Description: Pooled plaque sample will be collected and sent for DNA Extraction by PCR for assessment of levels of PGingivalis
Study: NCT00955058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCP
Description: Daily For 3 months
Study: NCT03049449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells
Description: Dose-escalation trial starting dose: 0.3x10\^6 Chimeric Antigen Receptor (CAR)+ T cells/kg (weight based dosing) (up to a maximum dose of 18x10\^6 CAR+ T cells/kg) infuse on day 0
Study: NCT02503046

Intervention type: GENETIC
Intervention: Estimation of P.Gingivalis levels
Description: Pooled plaque sample will be collected and sent for DNA Extraction by PCR for assessment of levels of PGingivalis
Study: NCT03231683

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remifentanil
Description: Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
Study: NCT02719561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue Intervention
Description: The Fatigue Intervention will include education, energy conservation and activity promotion
Study: NCT00592774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007 (perampanel)
Description: 2 mg titrated up to 8 mg maximum; taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007 (perampanel)
Description: 2 mg titrated up to 8 mg maximum; taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007 (perampanel)
Description: 2 mg titrated up to 8 mg maximum; taken once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mg titrated up to 8 mg maximum; taken once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 mg titrated up to 8 mg maximum; taken once daily.
Study: NCT04363151

Intervention type: OTHER
Intervention: No intervention.
Study: NCT02847572

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cataract Surgery
Description: All patients wil be having intraocular lens surgery
Study: NCT03896347

Intervention type: OTHER
Intervention: ViBone®
Description: Viable bone allograft

Intervention type: OTHER
Intervention: ViBone®
Description: Viable bone allograft

Intervention type: OTHER
Intervention: ViBone®
Description: Viable bone allograft

Intervention type: OTHER
Intervention: Demineralized Bone Matrix
Description: Demineralized Bone Matrix

Intervention type: OTHER
Intervention: Demineralized Bone Matrix
Description: Demineralized Bone Matrix

Intervention type: OTHER
Intervention: Demineralized Bone Matrix
Description: Demineralized Bone Matrix
Study: NCT03049449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 or 500 mg/m\^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
Study: NCT01724957

Intervention type: PROCEDURE
Intervention: Intracoronary ECG
Description: Recording of icECG from the tip of PCI guidewire. The wire end is connected through alligator clips to V-lead from surface ECG
Study: NCT02555163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HoLERBT
Description: Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cTURBT
Description: using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces
Study: NCT02281890

Intervention type: OTHER
Intervention: Proven sepsis
Description: Exposure is proven sepsis
Study: NCT02069691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality-cycling training system
Study: NCT01627418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy Voucher
Description: Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No intervention : control arm
Description: Do not receive the money or pamphlet in the initial study year
Study: NCT01808560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow Pre-Treatment
Description: The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow Post-treatment
Description: The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
Study: NCT02493647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Love, Sex, & Choices
Description: Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods. Undiagnosed HIV is a significant factor fueling the epidemic. Recruitment into the study will be via Facebook or traditional on the ground.